NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial

PrimeC demonstrated a clinically meaningful effect on quality of life and on complication free-survival for patients with ALSStandard ALS Measure ALSFRS-R already demonstrated a statistically...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Israel ,Canada ,Italy ,Ferenc Tracik ,Prnewswire Neurosense Therapeutics Ltd ,European Medicines Agency ,Linkedin ,Drug Administration ,Neurosense Therapeutics Ltd ,Exchange Commission On ,Exchange Commission ,Nasdaq ,Sense Therapeutics ,Advanced Stage Free Survival ,Chief Medical ,Rating Scale Revised ,Slow Vital Capacity ,Per Protocol ,Alon Ben Noon ,Orphan Drug Designation ,European Medicines ,Investigator Initiated Trial ,Tos Advanced Stage Free Survival ,Tos Advanced Stage ,Neurosense Therapeutic ,Annual Report ,Neurosense Therapeutics ,Markets ,